<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="45143">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02518620</url>
  </required_header>
  <id_info>
    <org_study_id>ALX0061-C203</org_study_id>
    <secondary_id>2014-003034-42</secondary_id>
    <nct_id>NCT02518620</nct_id>
  </id_info>
  <brief_title>An Extension Study Assessing the Long-Term Efficacy and Safety of Subcutaneous ALX-0061 in Subjects With Rheumatoid Arthritis</brief_title>
  <official_title>A Phase II Multicenter, Open-Label Extension Study Assessing the Long-Term Efficacy and Safety of Subcutaneous ALX-0061 in Subjects With Moderate to Severe Rheumatoid Arthritis Who Have Completed One of the Preceding Phase IIb Studies With ALX 0061</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ablynx</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ablynx</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to evaluate the long-term efficacy and safety of ALX-0061
      administered subcutaneously (s.c.) to subjects with active Rheumatoid Arthritis (RA).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2015</start_date>
  <primary_completion_date type="Anticipated">September 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of subjects with American College of Rheumatology (ACR) response.</measure>
    <time_frame>Up to 104 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in disease activity using Disease Activity Score (DAS28, Simplified Disease Activity Index (SDAI) and Clinical Disease Activity Index (CDAI).</measure>
    <time_frame>Up to 104 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of subjects with European League Against Rheumatism (EULAR) response.</measure>
    <time_frame>Up to 104 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of subjects in remission using DAS28, SDAI, CDAI and Boolean defined remission criteria.</measure>
    <time_frame>Up to 104 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI).</measure>
    <time_frame>Up to 104 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in physical and mental component scores of Short Form Health Survey (SF-36).</measure>
    <time_frame>Up to 104 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue).</measure>
    <time_frame>Up to 104 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Determination of anti-ALX-0061 antibodies.</measure>
    <time_frame>Up to 114 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Determination of ALX-0061 serum levels.</measure>
    <time_frame>Up to 104 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The incidence of Adverse Events and Serious Adverse Events.</measure>
    <time_frame>Up to 114 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">501</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>ALX-0061</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ALX-0061</intervention_name>
    <description>Multicenter open-label extension study</description>
    <arm_group_label>ALX-0061</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Must have been eligible for one of the preceding Phase IIb studies with ALX- 0061
             (study ALX0061-C201 or ALX0061-C202), have been randomized to placebo or one of the
             ALX-0061 arms (subjects randomized to tocilizumab [TCZ] in study ALX0061-C202 are not
             eligible).

          -  Must have reached a response at the end of treatment visit in the preceding Phase IIb
             ALX0061-C201, or ALX0061-C202 study.

          -  Others as defined in the protocol

        Exclusion Criteria:

          -  Received tocilizumab during the previous Study ALX0061-C202.

          -  Others as defined in the protocol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ablynx Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Ablynx</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ablynx NV Belgium</last_name>
    <phone>+3292620000</phone>
    <email>clinicaltrials@ablynx.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Investigator Site</name>
      <address>
        <city>Brussels</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ablynx NV Belgium</last_name>
      <email>clinicaltrials@ablynx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator Site 2</name>
      <address>
        <city>Brussels</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ablynx NV Belgium</last_name>
      <email>clinicaltrials@ablynx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator Site</name>
      <address>
        <city>Ghent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ablynx NV Belgium</last_name>
      <email>clinicaltrials@ablynx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator Site</name>
      <address>
        <city>Liège</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ablynx NV Belgium</last_name>
      <email>clinicaltrials@ablynx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator Site</name>
      <address>
        <city>Burgas</city>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ablynx NV Belgium</last_name>
      <email>clinicaltrials@ablynx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator Site</name>
      <address>
        <city>Plovdiv</city>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ablynx NV Belgium</last_name>
      <email>clinicaltrials@ablynx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator Site</name>
      <address>
        <city>Ruse</city>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ablynx NV Belgium</last_name>
      <email>clinicaltrials@ablynx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator Site 1</name>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ablynx NV Belgium</last_name>
      <email>clinicaltrials@blynx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator Site 2</name>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ablynx NV Belgium</last_name>
      <email>clinicaltrials@ablynx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator Site 5</name>
      <address>
        <city>Tbilisi</city>
        <zip>0102</zip>
        <country>Georgia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ablynx NV Belgium</last_name>
      <email>clinicaltrials@ablynx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator Site 1</name>
      <address>
        <city>Tbilisi</city>
        <zip>0159</zip>
        <country>Georgia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ablynx NV Belgium</last_name>
      <email>clinicaltrials@ablynx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator Site 2</name>
      <address>
        <city>Tbilisi</city>
        <zip>0159</zip>
        <country>Georgia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ablynx NV Belgium</last_name>
      <email>clinicaltrials@ablynx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator Site 4</name>
      <address>
        <city>Tbilisi</city>
        <zip>0160</zip>
        <country>Georgia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ablynx NV Belgium</last_name>
      <email>clinicaltrials@ablynx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator Site 3</name>
      <address>
        <city>Tbilisi</city>
        <zip>0179</zip>
        <country>Georgia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ablynx NV Belgium</last_name>
      <email>clinicaltrials@ablynx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator Site</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ablynx NV Belgium</last_name>
      <email>clinicaltrials@ablynx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator Site</name>
      <address>
        <city>Baja</city>
        <zip>6500</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ablynx NV Belgium</last_name>
      <email>clinicaltrials@ablynx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator Site</name>
      <address>
        <city>Gyula</city>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ablynx NV Belgium</last_name>
      <email>clinicaltrials@ablynx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator Site</name>
      <address>
        <city>Szikszó</city>
        <zip>3800</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ablynx NV Belgium</last_name>
      <email>clinicaltrials@ablynx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator Site</name>
      <address>
        <city>Szombathely</city>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ablynx NV Belgium</last_name>
      <email>clinicaltrials@ablynx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator Site</name>
      <address>
        <city>Székesfehérvar</city>
        <zip>8000</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ablynx NV Belgium</last_name>
      <email>clinicaltrials@ablynx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator Site</name>
      <address>
        <city>Veszprém</city>
        <zip>8200</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ablynx NV Belgium</last_name>
      <email>clinicaltrials@ablynx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator Site 1</name>
      <address>
        <city>Skopje</city>
        <country>Macedonia, The Former Yugoslav Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ablynx NV Belgium</last_name>
      <email>clinicaltrials@ablynx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator Site 2</name>
      <address>
        <city>Skopje</city>
        <country>Macedonia, The Former Yugoslav Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ablynx NV Belgium</last_name>
      <email>clinicaltrials@ablynx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator Site</name>
      <address>
        <city>Chisinau</city>
        <zip>2025</zip>
        <country>Moldova, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ablynx NV Belgium</last_name>
      <email>clinicaltrials@ablynx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator Site</name>
      <address>
        <city>Bydgoszcz</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ablynx NV Belgium</last_name>
      <email>clinicaltrials@ablynx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator Site</name>
      <address>
        <city>Gdynia</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ablynx NV Belgium</last_name>
      <email>clinicaltrials@ablynx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator Site</name>
      <address>
        <city>Grodzisk</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ablynx NV Belgium</last_name>
      <email>clinicaltrials@ablynx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator Site</name>
      <address>
        <city>Katowice</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ablynx NV Belgium</last_name>
      <email>clinicaltrials@ablynx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator Site</name>
      <address>
        <city>Lublin</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ablynx NV Belgium</last_name>
      <email>clinicaltrials@ablynx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator Site</name>
      <address>
        <city>Poznan</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ablynx NV Belgium</last_name>
      <email>clinicaltrials@ablynx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator Site</name>
      <address>
        <city>Sochaczew</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ablynx NV Belgium</last_name>
      <email>clinicaltrials@ablynx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator Site</name>
      <address>
        <city>Torun</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ablynx NV Belgium</last_name>
      <email>clinicaltrials@ablynx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator Site 1</name>
      <address>
        <city>Warszawa</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ablynx NV Belgium</last_name>
      <email>clinicaltrials@ablynx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator Site 2</name>
      <address>
        <city>Warszawa</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ablynx NV Belgium</last_name>
      <email>clinicaltrials@ablynx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator Site 1</name>
      <address>
        <city>Belgrade</city>
        <country>Serbia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ablynx NV Belgium</last_name>
      <email>clinicaltrials@ablynx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator Site 2</name>
      <address>
        <city>Belgrade</city>
        <country>Serbia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ablynx NV Belgium</last_name>
      <email>clinicaltrials@ablynx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator Site</name>
      <address>
        <city>Niska Banja</city>
        <country>Serbia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ablynx NV Belgium</last_name>
      <email>clinicaltrials@ablynx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator Site</name>
      <address>
        <city>Santander</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ablynx NV Belgium</last_name>
      <email>clinicaltrials@ablynx.Com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator Site</name>
      <address>
        <city>Santiago de Compostela</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ablynx NV Belgium</last_name>
      <email>clinicaltrials@ablynx.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Bulgaria</country>
    <country>Georgia</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Macedonia, The Former Yugoslav Republic of</country>
    <country>Moldova, Republic of</country>
    <country>Poland</country>
    <country>Serbia</country>
    <country>Spain</country>
  </location_countries>
  <verification_date>September 2016</verification_date>
  <lastchanged_date>September 12, 2016</lastchanged_date>
  <firstreceived_date>August 6, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
